Literature DB >> 24252544

Scorpion toxins for the reversal of BoNT-induced paralysis.

Colin A Lowery1, Michael Adler, Andrew Borrell, Kim D Janda.   

Abstract

The botulinum neurotoxins, characterized by their neuromuscular paralytic effects, are the most toxic proteins known to man. Due to their extreme potency, ease of production, and duration of activity, the BoNT proteins have been classified by the Centers for Disease Control as high threat agents for bioterrorism. In an attempt to discover effective BoNT therapeutics, we have pursued a strategy in which we leverage the blockade of K(+) channels that ultimately results in the reversal of neuromuscular paralysis. Towards this end, we utilized peptides derived from scorpion venom that are highly potent K(+) channel blockers. Herein, we report the synthesis of charybdotoxin, a 37 amino acid peptide, and detail its activity, along with iberiotoxin and margatoxin, in a mouse phrenic nerve hemidiaphragm assay in the absence and the presence of BoNT/A.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aminopyridine; Bioterrorism; Botulinum neurotoxin; Phrenic nerve hemidiaphragm; Scorpion toxin

Mesh:

Substances:

Year:  2013        PMID: 24252544      PMCID: PMC3869784          DOI: 10.1016/j.bmcl.2013.10.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  37 in total

Review 1.  Peptides and genes coding for scorpion toxins that affect ion-channels.

Authors:  L D Possani; E Merino; M Corona; F Bolivar; B Becerril
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

Review 2.  Current views on scorpion toxins specific for K+-channels.

Authors:  Ricardo C Rodríguez de la Vega; Lourival D Possani
Journal:  Toxicon       Date:  2004-06-15       Impact factor: 3.033

Review 3.  Toxin determinants required for interaction with voltage-gated K+ channels.

Authors:  Besma Jouirou; Stéphanie Mouhat; Nicolas Andreotti; Michel De Waard; Jean-Marc Sabatier
Journal:  Toxicon       Date:  2004-06-15       Impact factor: 3.033

4.  Structural biology. How a neurotoxin survives.

Authors:  Michael Adler
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

5.  The nature of the receptor site for the reversible K+ channel blocking by aminopyridines.

Authors:  Camelia Muñoz-Caro; Alfonso Niño
Journal:  Biophys Chem       Date:  2002-04-10       Impact factor: 2.352

6.  Iberiotoxin-induced block of Ca2+-activated K+ channels induces dihydropyridine sensitivity of ACh release from mammalian motor nerve terminals.

Authors:  Michael T Flink; William D Atchison
Journal:  J Pharmacol Exp Ther       Date:  2003-01-24       Impact factor: 4.030

7.  Botulinum toxin type A: kinetics of calcium dependent paralysis of the neuromuscular junction and antagonism by drugs and animal toxins.

Authors:  P Metezeau; M Desban
Journal:  Toxicon       Date:  1982       Impact factor: 3.033

8.  Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.

Authors:  Michael Adler; Sharad S Deshpande; James P Apland; Bridget Murray; Andrew Borrell
Journal:  Neurochem Int       Date:  2012-07-25       Impact factor: 3.921

9.  Effect of age on body distribution of Tityustoxin from Tityus serrulatus scorpion venom in rats.

Authors:  Elzíria A Nunan; Márcio F D Moraes; Valbert N Cardoso; Tasso Moraes-Santos
Journal:  Life Sci       Date:  2003-06-06       Impact factor: 5.037

10.  Facile preparation of disulfide-bridged peptides using the polymer-supported oxidant CLEAR-OX.

Authors:  K Darlak; D Wiegandt Long; A Czerwinski; M Darlak; F Valenzuela; A F Spatola; G Barany
Journal:  J Pept Res       Date:  2004-03
View more
  1 in total

1.  A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.

Authors:  Tyler L Harris; Colin A Lowery; Mark S Hixon; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2014-07-11       Impact factor: 4.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.